Evidence map›Paper›PMID 31912405›Full record

SynthesisInternational ophthalmology2020

Assessment of reporting quality of meta-analyses of randomized controlled trials in neovascular age-related macular degeneration published from April 2014 to May 2018 using prisma statement.

Ourania Tounakaki, Αngeliki Tsakou, Angelakis Malamas, Doxani Chrisoula, Stefanidis Ioannis, Zintzaras Elias

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in International ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ourania TounakakiDepartment of Ophthalmology, Achilopouleio General Hospital, Polimeri 134, 38222, Vólos, Greece.
Αngeliki Tsakou2nd Department of Internal Medicine, Achilopouleio General Hospital, Polimeri 143, Vólos, Greece.
Angelakis MalamasDepartment of Ophthalmology, Achilopouleio General Hospital, Polimeri 134, 38222, Vólos, Greece. malamasaggelos@gmail.com.ORCID http://orcid.org/0000-0002-6239-0564
Doxani ChrisoulaDepartment of Biomathematics, University of Thessaly School of Medicine, Mezourlo, Larissa, Greece.
Stefanidis IoannisDepartment of Nephrology, Medical School, University of Thessaly, Mezourlo, Larissa, Greece.
Zintzaras EliasDepartment of Biostatistics and Clinical Bioinformatics, Faculty of Medicine, University of Thessaly, Mezourlo, Larissa, Greece.
Agios Pavlos General Hospital · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the reporting quality of meta-analysis on neovascular age-related macular degeneration treatment and safety profile based on PRISMA statement.

methodsElectronic search performed in August 2018 to retrieve meta-analyses published from April 2014 to May 2018. PRISMA evaluation was determined by total scores of individual meta-analyses and items scores. Statistical analysis of parameters affecting the reporting evaluation included subgroup multivariate analysis and regression analysis.

resultsTwelve meta-analyses were finally included, three being Cochrane systematic reviews. Mean PRISMA score is 23.2/27 (86.1%). Eleven PRISMA ITEMS had significantly higher %score in 12 meta-analyses than in nine non-Cochrane meta-analyses measurements. Positive strong correlation identified between PRISMA %score and journal impact factor (JIF). Multivariate analysis between high-scored and low-scored meta-analyses established difference in means of several parameters (JIF, Publication Year).

conclusionsThe evaluation of overall reporting quality was favorable. As expected, the key role of several characteristics of meta-analysis affects this quality. Under-reporting of specific items (protocol, search strategy and assessment of risk of bias) indicates the urgency for PRISMA compliance.

Indexed as

Disease ManagementQuality ImprovementHumansRandomized Controlled Trials as TopicWet Macular DegenerationAMDAnti-VEGFMeta-analysisPRISMAReporting qualitySystematic reviews

Identifiers

PMID31912405
OpenAlexW3000631747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.